Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
This study has been terminated.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: December 4, 2002
Last updated: November 4, 2013
Last verified: November 2013
The purpose of this study is to determine the overall survival of patients diagnosed with Stage 3b or 4 non-small cell lung cancer (NSCLC) treated with an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 66336) in combination with paclitaxel and carboplatin with that of patients treated with placebo in combination with paclitaxel and carboplatin.
Carcinoma, Non-small-cell Lung
Drug: Lonafarnib (SARASAR)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
||A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2004 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female
- Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol.
- Age greater than or equal to 18 years old
- ECOG performance status of 0 to 1
- Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified.
- Meets protocol requirements for specified laboratory values
- Written informed consent
- Appropriate use of effective contraception if of childbearing potential
- Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease
- Prior chemotherapy for any stage of NSCLC
- Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy
- Concurrent treatment or treatment within the last 2 years for any other malignancy
- Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication)
- Medical conditions that would interfere with taking oral medications
- Patients with bone metastases as the only site of disease
- Pregnant or nursing women
- Known HIV positivity or AIDS-related illness
- Patients with significant QTc prolongation at baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 4, 2002
||November 4, 2013
||United States: Food and Drug Administration
Keywords provided by Merck Sharp & Dohme Corp.:
Stage 3b or 4 (metastatic) non-small cell lung cancer
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 26, 2015
Carcinoma, Non-Small-Cell Lung
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action